Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a ch...

Descripció completa

Dades bibliogràfiques
Autors principals:	Maini, R, St Clair, E, Breedveld, F, Furst, D, Kalden, J, Weisman, M, Smolen, J, Emery, P, Harriman, G, Feldmann, M, Lipsky, P
Format:	Journal article
Idioma:	English
Publicat:	1999

Ítems similars

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
per: Lipsky, P, et al.
Publicat: (2000)

Infliximab and methotrexate in the treatment of rheumatoid arthritis
per: Lipsky, P, et al.
Publicat: (2000)

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
per: Elliott, M, et al.
Publicat: (1994)

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
per: Maini, R, et al.
Publicat: (1998)

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
per: Furst, D, et al.
Publicat: (2000)

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
per: Elliot, M, et al.
Publicat: (2008)

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
per: Elliott, M, et al.
Publicat: (1993)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
per: Tanja Alexandra Stamm, et al.
Publicat: (2018-08-01)

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
per: Charles, P, et al.
Publicat: (2000)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
per: Maini, R, et al.
Publicat: (1999)

How does infliximab work in rheumatoid arthritis?
per: Maini, R, et al.
Publicat: (2002)

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
per: O’Dell JR, et al.
Publicat: (2018-07-01)

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.
per: Tak, P, et al.
Publicat: (1996)

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
per: Paleolog, E, et al.
Publicat: (1996)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
per: Delphine Dénarié, et al.
Publicat: (2017-01-01)

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.
per: Elliott, M, et al.
Publicat: (1994)

EVALUATION OF EFFICACY AND SAFETY OF COMPLEX TREATMENT WITH INFLIXIMAB AND METHOTREXATE COMPARING WITH METHOTREXATE MONOTHERAPY OF CHILDREN WITH JUVENILE POLYARTICULAR IDIOPATHIC ARTHRITIS
per: V. A. Kel'tsev, et al.
Publicat: (2012-03-01)

Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab
per: Giuseppe Rossi, et al.
Publicat: (2011-09-01)

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
per: Charles, P, et al.
Publicat: (1999)

Psoriatic flare after the concomitant administration of L-methylfolate and methotrexate
per: Roya S. Nazarian, BA, et al.
Publicat: (2017-01-01)

Activation of Methotrexate Prodrugs by Enzyme/Monoclonal Antibody Conjugates
per: Vitols K. S., et al.
Publicat: (1991-02-01)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
per: Yoon-Zi Kim, et al.
Publicat: (2023-09-01)

Refractory brainstem encephalitis mimicking progressive cerebral infarction: infliximab and methotrexate as a salvage immunotherapy
per: Sung-Ho Ahn, et al.
Publicat: (2021-06-01)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
per: E. Feist, et al.
Publicat: (2023-04-01)

Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy
per: Rattanakaemakorn P, et al.
Publicat: (2021-05-01)

Anaplastic Large Cell Lymphoma of the Colon in a Patient with Colonic Crohn Disease Treated with Infliximab and Methotrexate
per: Tushar Shukla, et al.
Publicat: (2014-01-01)

A Novel Case of Multicentric Reticulohistiocytosis Associated with Renal Cell Carcinoma Successfully Treated with Infliximab and Methotrexate
per: Suraj Patel, et al.
Publicat: (2023-01-01)

Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis
per: Maarit Tarkiainen, et al.
Publicat: (2022-11-01)

Protocol for production and expression of chimeric bovine-human monoclonal antibodies
per: Behnaz Heydarchi, et al.
Publicat: (2022-12-01)

Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
per: Hua Ye, et al.
Publicat: (2023-03-01)

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system
per: Kenji Onda, et al.
Publicat: (2023-02-01)

Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor alpha therapy in rheumatoid arthritis - Reply
per: Maini, R, et al.
Publicat: (1998)

Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.
per: Williams, R, et al.
Publicat: (2000)

Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients
per: Matthijs S. van der Leeuw, et al.
Publicat: (2023-05-01)

Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
per: Ekaterina Alexeeva, et al.
Publicat: (2019-10-01)

Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
per: William V. Padula, et al.
Publicat: (2015-01-01)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
per: Feldmann, M, et al.
Publicat: (1997)

Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis.
per: Feldmann, M, et al.
Publicat: (1994)

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
per: Williams, R, et al.
Publicat: (1992)

Anti‐tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
per: Lachlan Stranks, et al.
Publicat: (2022-08-01)